ClinicalTrials.gg
CompletedNCT02404558Updated Mar 28, 2016

Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis

A Phase 1 interventional study of sarilumab SAR153191 (REGN88) and tocilizumab in Rheumatoid Arthritis, sponsored by Sanofi. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-03-28.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.

Enrollment
17th of 22
30 · median 88
Started
2015
with 2 others
Phase 1
7 of 22
none open now
Registered
16th of 22
by date
Lead sponsor
14 of 22
Sanofi

Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 17th largest by enrollment, is one of 3 that started in 2015, is one of 7 in phase 1, and was the 16th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About sarilumab

sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing sarilumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Primary Objective:

To describe the safety and tolerability, including laboratory abnormalities following a single dose of sarilumab or tocilizumab administered subcutaneously (SC) as monotherapy in Japanese patients with rheumatoid arthritis (RA).

Secondary Objectives:

To describe the laboratory abnormalities (absolute neutrophil count [ANC], platelet counts, total cholesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL] cholesterol, and liver function tests [LFTs]) following a single dose of sarilumab or tocilizumab administered SC as monotherapy in Japanese patients with RA.

To describe the pharmacokinetics (PK) of sarilumab and tocilizumab.

Read the detailed description

Total study duration (per patient) is expected to be up to 71 days including screening (3 to 28 days before dosing).

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with rheumatoid arthritis (RA) as defined by the American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) 2010
  • Rheumatoid Arthritis Classification Criteria.
  • ACR Class I-III functional status, based on the 1991 revised criteria.

Exclusion criteria

Exclusion criteria:

  • Patients less than 20 years of age.
  • Prior treatment with any biologic anti-interleukin-6 (anti-IL-6) or interleukin-6 receptor (IL-6R) antagonist.
  • Any parenteral or intraarticular injection within 4 weeks prior to randomization.
  • Treatment with prednisone higher than 10 mg or equivalent per day, or change in dosage within 4 weeks prior to randomization.
  • Treatment with disease-modifying antirheumatic drugs (DMARDs), agents, tumor necrosis factor (TNF) antagonists or any other RA-directed biologic agents within a certain amount of time prior to randomization.
  • Participation in any clinical research study that evaluated an drug or therapy within 5 half-lives or 60 days of the screening visit, whichever is longer.
  • Active or suspected tuberculosis (TB) or at high risk of contracting TB.
  • Fever, or chronic, persistent, or recurring infection(s) requiring active treatment.
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Sarilumab

    Single subcutaneous (SC) dose of sarilumab

    Drug: sarilumab SAR153191 (REGN88)

  • Active comparator
    Tocilizumab

    Single SC dose of tocilizumab

    Drug: tocilizumab

Interventions

  • Pharmaceutical form:solution Route of administration: Subcutaneous injection

  • Pharmaceutical form:solution Route of administration: Subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percentage of patients with adverse events

    Time frame: 6 weeks

  2. Percentage of patients with potentially clinically significant laboratory abnormalities

    Time frame: 6 weeks

  3. Change from baseline in laboratory parameters (hematology and biochemistry)

    Time frame: Baseline, Day 15

  4. Weighted average of change from baseline in laboratory parameters (hematology and biochemistry)

    Time frame: Baseline, Day 15

Secondary outcomes

  1. Assessment of PK parameter: maximum concentration (Cmax)

    Time frame: Day 1 to Day 43

  2. Assessment of PK parameter: time to Cmax (tmax)

    Time frame: Day 1 to Day 43

  3. Assessment of PK parameter: area under the curve from zero time until the last measurable concentration (AUClast)

    Time frame: Day 1 to Day 43

  4. Change from baseline in laboratory parameters (hematology and biochemistry)

    Time frame: Baseline, Day 29 and Day 43

  5. Weighted average of change from baseline in laboratory parameters (hematology and biochemistry)

    Time frame: Baseline, Day 29 and Day 43

07

Study locations

3 sites
  • Investigational Site Number 392001
    Sendai-Shi, Japan
  • Investigational Site Number 392002
    Sendai-Shi, Japan
  • Investigational Site Number 392003
    Sendai-Shi, Japan
08

References and documents

Publications

  • Kovalenko P, Paccaly A, Boyapati A, Xu C, St John G, Nivens MC, Davis JD, Rippley R, DiCioccio AT. Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis. CPT Pharmacometrics Syst Pharmacol. 2020 Jul;9(7):405-416. doi: 10.1002/psp4.12534. Epub 2020 Jun 20. PubMed 32453485 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2015
First posted
Mar 31, 2015
Start
May 2015
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Last update
Mar 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02404558
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 31, 2015
Start date
May 2015
Primary completion
Mar 2016
Completion
Mar 2016
Last update
Mar 28, 2016

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarilumab

Start the discussion